Esperion Therapeutics to Present at 34th Annual J.P. Morgan

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Esperion Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ: ESPR ), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 34 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 13, 2016 at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time.

A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at  www.esperion.com . A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website for 90 days following the event.

Esperion’s Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with hypercholesterolemia by developing therapies to lower LDL-C. Esperion scientists discovered ETC-1002 and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both ETC-1002 and a fixed dose combination of ETC-1002 and ezetimibe with a particular focus on patients with hypercholesterolemia who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia. ETC-1002 (bempedoic acid), the Company’s lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. ETC-1002 inhibits cholesterol synthesis, decreases intracellular cholesterol, up-regulates LDL-receptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit  www.esperion.com  and follow us on Twitter at  https://twitter.com/EsperionInc .

Media Contact: Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wagner Logistics Gears Up for Major Expansion in Liberty

Updated Category News Views 34

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Continue Reading
JiMMYBAR! Unveils World's First Creatine Trail Mix

Updated Category News Views 25

The New Face of Snacking: Creatine Trail Mix I'll tell you right off the bat, JiMMYBAR! seems to be cornering the snack world with an odd—but interesting—twist. They've just launched the world's first Creatine + Protein Trail Mix, blending muscle-building nutrients with the classic crunch of trail mix. Sounds quirky, and it’s exclusive to their site, JiMMYBARs.com....

Continue Reading
Jaguar Promise Tackles College Cost for Texas Students

Updated Category News Views 25

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Continue Reading
Gourmia Introduces Ceramic-Coated Air Fryer at Costco

Updated Category News Views 23

A New Era for Home Cooking with Gourmia Stepping into the kitchen appliances arena with a dash of innovation, Gourmia has launched its first ceramic-coated air fryer, and it’s weaving its way exclusively onto the shelves of Costco. Now, it’s not just about frying anymore; it’s about adding style, efficiency, and a touch of healthy living to your countertop. But much...

Continue Reading
Oracle Announces AI-Driven QuickStart Platform Launch

Updated Category News Views 29

NetSuite's AI-First Step into the Market Well, here's the NYSE stirring the pot with Oracle NetSuite's fresh announcement—an AI-first platform called QuickStart. Sounds like they've got their sights set on early-stage tech startups, banking on those little guys to plug into AI tools they've already got in their toolkit. Claude, ChatGPT—these aren't new kids on the...

Continue Reading
Truck Drivers USA & Career Driver Unveil New Driver Agent

Updated Category News Views 41

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Continue Reading
Tessa AI: Revolutionizing Biomedical Research with AI

Updated Category News Views 23

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

Continue Reading
Vayo Debuts as Booking Holdings Eyes $100M Investment

Updated Category News Views 16

A travel revolution might just be on the horizon, courtesy of Booking Holdings' latest venture, Vayo. And they’re talking about throwing $100 million into it—subject to a few conditions, sure—but that’s not pocket change you toss around without a serious plan. Transforming Travel into a Seamless Experience Vayo’s got one job: making your travels less like a...

Continue Reading
AI-Powered Travel Transformation in Norway Revealed

Updated Category News Views 23

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

Continue Reading
Omega Point's MCP Secures Anthropic Verification

Updated Category News Views 25

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Class Action Against Fiserv, Inc. for Stockholders

Updated Category News Views 228

Introduction to the Class Action Against Fiserv, Inc. Are you a stockholder of Fiserv, Inc. (NASDAQ: FI) who has experienced considerable financial losses? If so, there is a growing concern among investors regarding the company’s recent financial disclosures. Fiserv is a notable player in the global payments and financial technology sector, and the ongoing developments...

Continue Reading
Senti Bio Engages Investors on Advances in AML Treatment

Updated Category News Views 111

Senti Bio Engages Investors on Advances in AML Treatment Recently, Senti Biosciences, Inc. (Nasdaq: SNTI) participated in an enlightening virtual investor segment titled "What This Means." This segment highlighted the company's ongoing efforts in developing innovative therapies for acute myeloid leukemia (AML), focusing on the Phase 2 dose and schedule selection for their...

Continue Reading
Cognizant Technology Solutions: Target Price Boost Amid Caution

Updated Category News Views 146

Cognizant Technology Solutions Receives Target Price Increase Recently, Deutsche Bank adjusted its outlook for Cognizant Technology Solutions (NASDAQ: CTSH) by increasing its price target from $70 to $80. This move highlights a new assessment of the company's growth potential within the current economic climate affecting the IT Services sector. The bank's analyst...

Continue Reading
Investors Encouraged to Act on RxSight, Inc. Legal Matter

Updated Category News Views 146

Investors Alerted Regarding RxSight, Inc. Class Action The Schall Law Firm, a notable player in securities class action lawsuits, is reminding investors about an active class action lawsuit against RxSight, Inc. (NASDAQ: RXST) related to potential securities fraud. The firm argues that RxSight has potentially violated significant sections of the Securities Exchange Act....

Continue Reading
Comstock Inc. Prepares for Exciting Presentation at NobleCon

Updated Category News Views 115

Comstock Inc. to Shine at NobleCon20 Conference Comstock Inc. announced an exciting engagement at NobleCon20, the annual Emerging Growth Equity Conference hosted by Noble Capital Markets. On this notable occasion, Corrado De Gasperis, the Executive Chairman and CEO of Comstock, will take the stage to highlight the company's innovative strategies in the clean energy...

Continue Reading